FDA Approves Yet Another Interchangeable Biosimilar and Another Biosimilar | McDonnell Boehnen Hulbert & Berghoff LLP

On October 3, 2023, the U.S. Food and Drug Administration (FDA) announced approval of Biogen's Byooviz (ranibizumab-nuna) as an interchangeable biosimilar to Genentech's Lucentis...

Related Keywords

Choroidal Neovascularization ,Genentech Lucentis ,Genentech Avastin ,Drug Administration ,Mcdonnell Boehnen Hulbert Berghoff ,Mcdonnell Boehnen Hulbert ,Age Related Macular Degeneration ,Macular Edema Following Retinal Vein Occlusion ,Myopic Choroidal Neovascularization ,Bio Thera Solution ,